The expression of EGFR, as well as most solid tumor antigens, is not restricted to malignant cells only; thus, multiple CAR T cell approaches have been tested with the aim to limit the on-target, off-tumor toxicities of for instance EGFR-targeting CAR T cells and increase their safety [60,61]. Here, EGFR is linked to neoplasm.